NCT01627340 - Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Engerix™-B in Adults With or Without Type 2 Diabetes Mellitus | Biotech Hunter

Enrollment

667

Participants

Timeline

Start Date

July 24, 2012

Primary Completion Date

December 18, 2013

Study Completion Date

December 18, 2013

Conditions

Hepatitis B

Interventions

BIOLOGICAL

Engerix™-B vaccine

3 doses administered intramuscularly (IM) in the deltoid region of the non-dominant arm.

Trial Locations (22)

3010

GSK Investigational Site, Rotorua

3021

GSK Investigational Site, St Albans

3128

GSK Investigational Site, Box Hill

3240

GSK Investigational Site, Hamilton

4029

GSK Investigational Site, Herston

6021

GSK Investigational Site, Wellington

13760

GSK Investigational Site, Endwell

30281

GSK Investigational Site, Stockbridge

35802

GSK Investigational Site, Huntsville

37203

GSK Investigational Site, Nashville

44122

GSK Investigational Site, Cleveland

46545

GSK Investigational Site, Mishawaka

67207

GSK Investigational Site, Wichita

83642

GSK Investigational Site, Boise

84109

GSK Investigational Site, Salt Lake City

98801

GSK Investigational Site, Wenatchee

B2N 1L2

GSK Investigational Site, Truro

P3E 1H5

GSK Investigational Site, Greater Sudbury

N2G 1E8

GSK Investigational Site, Kitchener

G1E 7G9

GSK Investigational Site, Québec

G1W 4R4

GSK Investigational Site, Ste-Foy

Unknown

GSK Investigational Site, Takapuna Auckland